Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma Real World Evidence from the French Early Access Program - Archive ouverte HAL Access content directly
Journal Articles Blood Year : 2018

Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma Real World Evidence from the French Early Access Program

Lysiane Molina
  • Function : Author
Remy Dulery
Laurent Dercle

Dates and versions

hal-02076926 , version 1 (22-03-2019)

Identifiers

Cite

Roch Houot, Guillaume Manson, Jean-Baptiste Mear, Charles Herbaux, Jean Marc Schiano de Collela, et al.. Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma Real World Evidence from the French Early Access Program. Blood, 2018, 132 (1), pp.1638. ⟨10.1182/blood-2018-99-110960⟩. ⟨hal-02076926⟩
60 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More